Cencora, Inc. (COR) stock
CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3021% above fair value
$350.56−6.38 (-1.79%)
Close on Nov 17, 2026Market cap $66.90BP/E 26.0Yield 0.63%
Cencora operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cencora's operating income for the twelve months ending Jun 30, 2026 was $3.04B, up 11.1% year over year. For fiscal 2025 it was $2.63B, up 20.8% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $2.63B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.63B | +20.8% |
| FY2024 | Sep 30, 2024 | $2.18B | -7.1% |
| FY2023 | Sep 30, 2023 | $2.34B | -1.1% |
| FY2022 | Sep 30, 2022 | $2.37B | +0.5% |
| FY2021 | Sep 30, 2021 | $2.35B | – |
| FY2020 | Sep 30, 2020 | -$5.14B | -561.8% |
| FY2019 | Sep 30, 2019 | $1.11B | -23.0% |
| FY2018 | Sep 30, 2018 | $1.44B | +36.2% |
| FY2017 | Sep 30, 2017 | $1.06B | -30.5% |
| FY2016 | Sep 30, 2016 | $1.53B | +261.4% |
| FY2015 | Sep 30, 2015 | $422.22M | -46.0% |
| FY2014 | Sep 30, 2014 | $782.09M | -12.9% |
| FY2013 | Sep 30, 2013 | $898.40M | -31.1% |
| FY2012 | Sep 30, 2012 | $1.30B | +9.6% |
| FY2011 | Sep 30, 2011 | $1.19B | +8.9% |
| FY2010 | Sep 30, 2010 | $1.09B | +23.6% |
| FY2009 | Sep 30, 2009 | $883.75M | +6.8% |
| FY2008 | Sep 30, 2008 | $827.86M | +5.0% |
| FY2007 | Sep 30, 2007 | $788.74M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $1.12B | +29.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $1.14B | +10.3% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $760.45M | +7.7% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $18.50M | -85.4% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $867.65M | +29.0% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $1.04B | +87.3% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $706.25M | -14.2% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $126.64M | -73.4% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $672.48M | +0.4% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $553.26M | -1.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $822.88M | +30.0% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $476.94M | +4.9% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $670.13M | +37.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $560.52M | -28.2% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $633.14M | -1.7% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $454.52M | -19.1% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $487.30M | -21.5% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $780.16M | +25.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $644.41M | +17.8% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $561.90M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $620.73M | +53.3% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $624.35M | +101.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $547.23M | +107.7% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$6.11B | -3499.2% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $404.83M | -0.5% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $309.52M | +550.7% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $263.44M | -44.9% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $179.84M | +16.7% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $406.69M | +4.5% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $47.57M | -90.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $477.82M | +14.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $154.10M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $389.20M | +128.4% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $481.42M | -23.0% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $418.97M | +4.7% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$135.00M | -160.1% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $170.38M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $624.98M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $399.99M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $224.80M | – |
See a number that looks wrong?